CA-SCIENTIST.COM
2.12.2020 10:35:04 CET | Business Wire | Press release
Scientist.com, the healthcare industry’s leading marketplace for outsourced research, has partnered with Enhancing Quality In Preclinical Data (EQIPD) to help define and improve data quality within preclinical research. A self-certification questionnaire is now accessible via Scientist.com’s award-winning compliance solution COMPLi®, allowing global suppliers to self-certify prior to working with biopharma research organizations. With this self-certification, suppliers demonstrate their data integrity processes and procedures to potential clients.
“EQIPD’s holistic approach to tackling the challenges related to data quality within preclinical research aligns with our COMPLi standards, which provides researchers with the proper due diligence necessary to source from suppliers of preclinical services,” stated Matt McLoughlin, VP of Categories & Compliance. “We are working with EQIPD to ensure data integrity is at the heart of research.”
Currently, there are no globally accepted quality standards when it comes to reporting data generated by preclinical research. To define and implement such standards EQIPD has formed a consortium of key stakeholders that includes large pharma (including a number of current Scientist.com clients), biotech companies, academia and compliance solutions. The consortium works closely with Stakeholder Group members such as Scientist.com. EQIPD is looking to develop best practices that can be shared across R&D in the life sciences.
“Use of the EQIPD-derived tools by stakeholders such as Scientist.com enables EQIPD to deliver its mission of improving data integrity standards across the global research community,” stated Anton Bespalov of PAASP, an EQIPD consortium member. “Their COMPLi platform can increase visibility to our work and ensure it aligns completely with the goals of EQIPD moving forward.”
“Including a self-certification questionnaire, based on the EQIPD standard, within COMPLi, streamlines and harmonises the data quality and data integrity due diligence process applied by biopharma research organizations during the on-boarding of preclinical service suppliers,” stated Sandrine Bongiovanni of Novartis Pharma AG.
Research organizations looking to self-certify or learn more about COMPLi can visit https://www.scientist.com/compli/
About Scientist.com
Scientist.com is the pharmaceutical industry’s leading AI-powered marketplace for outsourced R&D. The marketplace simplifies R&D sourcing, saves time and money, reduces risk, and provides access to the latest innovative tools and technologies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, over 80 biotechnology companies, the Biotechnology Innovation Organization (BIO), and the US National Institutes of Health (NIH).
Join Scientist.com on social media: LinkedIn , Twitter , YouTube , Facebook , and Instagram
About EQIPD
The Enhancing Quality in Preclinical Data consortium (EQIPD; previously "European Quality in Preclinical Data") was founded in 2017 by 29 academic institutions, pharmaceutical companies, and SMEs from 8 countries (https://quality-preclinical-data.eu ).
Supported through the European Union’s Innovative Medicines Initiative (IMI), major deliverables of the EQIPD consortium were the development of a novel preclinical research quality system that could be applied in both the public and private sectors, and the generation of online training capacity in good research practice.
The consortium works closely with a large group of associated collaborators, advisors and stakeholders drawn from nearly 100 organizations in Europe and the US and including research institutions, publishers, funders, learned societies and professional societies.
Follow EQIPD on social media:
https://www.facebook.com/EQIPD/
https://twitter.com/EQIPD
https://www.linkedin.com/groups/12074241/profile
View source version on businesswire.com: https://www.businesswire.com/news/home/20201201005416/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 13:00:00 CEST | Press release
Partnership includes FIFA tournaments and events from 2031Agreement encompasses both physical and digital collectibles, and for the first time brings the player jersey patch program to international footballPre-match press conferences for the FIFA World Cup Final to take place at Fanatics Fest on Friday, 17 July 2026 In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football tradin
DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 11:21:00 CEST | Press release
Poster presented at ESMO Breast Cancer 2026: Exploring health policy and real-world treatment strategies for early-stage HER2-positive breast cancer across Europe. The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom